简介:目的:探讨阈值下微脉冲激光联合玻璃体注射抗血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)治疗视网膜分支静脉阻塞(branchretinalveinocclusion,BRVO)继发黄斑水肿的疗效。方法:回顾性分析经荧光眼底血管造影(FFA)和相干光断层扫描(OCT)检查确诊为BRVO且病史〈3mo的BRVO继发黄斑水肿患者16例16眼,8眼予玻璃体腔注射抗VEGF药物治疗联合577nm阈值下微脉冲激光(微脉冲组),8眼予玻璃体腔注射抗VEGF药物治疗联合传统格栅样激光光凝(格栅光凝组)。观察治疗前及治疗后6mo两组患者的最佳矫正视力(bestcorrectedvisualacuity,BCVA)及黄斑中心凹厚度(centralfovealthickness,CFT)。结果:治疗后6mo的BCVA:微脉冲组由治疗前的0.34±0.18提高到0.07±0.01,差异有统计学意义(P〈0.01),格栅光凝组由治疗前的0.75±0.52提高到0.15±0.18,差异有统计学意义(P〈0.01),两组治疗后比较差异无统计学意义(P〉0.05)。治疗后6mo的CFT:微脉冲组由治疗前的362.25±119.33μm降低至232.25±56.56μm,差异有统计学意义(P〈0.05),格栅光凝组由治疗前的419.75±96.30μm降低至229.25±43.96μm,差异有统计学意义(P〈0.01),两组治疗后比较差异无统计学意义(P〉0.05)。结论:治疗CRVO合并黄斑水肿,577nm阈下微脉冲激光联合玻璃体腔注射抗VEGF药物治疗与传统格栅光凝联合玻璃体腔注射抗VEGF药物治疗具有同样的良好疗效。
简介:目的:探讨外伤性持续黄斑水肿患者玻璃体腔注射曲安奈德(triamicinoloneacetonide,TA)治疗后黄斑区功能的变化.方法:外伤性持续黄斑水肿眼20例20眼,给予玻璃体腔内注射0.1mLTA.治疗后随访3mo,观察治疗前后视力、黄斑区神经上皮厚度、多焦视网膜电图(mfERG)N1,P1波的潜伏期和反应密度等变化情况.结果:治疗后3mo,矫正视力0.78±0.11,与治疗前(0.21±0.09)相比,差异有显著统计学意义(P<0.01).治疗后3mo,黄斑区神经上皮平均厚度158.00±13.73μm,与治疗前(321.67±42.24μm)相比,差异有显著统计学意义(P<001).治疗后3mo,mfERG1,2环N1,P1波潜伏期和反应密度与治疗前相比明显下降,差异有显著统计学意义(P<0.01).结论:TA治疗外伤所致持续性黄斑水肿是一种有效的方法;水肿消退后黄斑区功能得到改善.
简介:目的:观察和分析角膜塑形镜治疗后角膜形态的变化,评估角膜塑形镜治疗后光学区偏离中心对控制近视的影响。方法:回顾性临床研究。对134例134眼近视患儿配戴角膜塑形镜矫治近视,平均年龄10.66±1.79岁,均取右眼数据进行研究。分别在戴镜前及戴镜后3、6、12、18、24mo检查视力、眼轴和角膜地形图。使用SPSS19.0进行统计学分析。结果:戴镜后3、6、12、18、24mo的光学区偏瞳孔中心距离分别为0.84±0.45、0.77±0.40、0.79±0.41、0.78±0.41、0.79±0.42mm,差异无统计学意义(F=1.187,P=0.319)。戴镜24mo后平均光学区偏中心距离为0.79±0.35mm,眼轴增长均值为0.32±0.30mm。戴镜24mo后平均偏中心距离轻度(<0.5mm)、中度(0.5~1.0mm)、重度(>1.0mm)的眼轴增长分别为0.45±0.34、0.32±0.28、0.23±0.29mm,差异有统计学意义(F=3.825,P=0.024)。戴镜后的平均偏中心距离和眼轴增长经线性回归分析,其线性关系有统计学意义(F=7.246,P=0.008),线性回归方程Y=0.478-0.194X。戴镜24mo后,18眼有重影,其偏中心距离均值1.18±0.36mm;116眼无重影,其偏中心距离均值0.73±0.31mm,偏中心距离比较差异有统计学意义(t=5.59,P<0.01)。结论:光学区偏中心距离在角膜塑形镜治疗3mo后趋于稳定,且对控制近视的效果和视觉质量有影响。
简介:AIM:Toassesstheeffectivenessofimmunosuppressantsintheprophylaxisofcornealallograftrejectionafterhigh-riskkeratoplastyandnormal-riskkeratoplasty.METHODS:WesearchedtheCochraneCentralRegisterofControlledTrials(CENTRAL),MEDLINE,EMBASE,CNKI,VIPandreferencelistsofarticles.Dateofmostrecentsearch:18June,2011.Allrandomisedcontrolledtrials(RCTs)assessingtheuseofimmunosupressantsinthepreventionofgraftrejection,irrespectiveofpublicationlanguage.Twoauthorsassessedtrialqualityandextracteddataindependently.Onlydichotomousoutcomes(cleargraftsurvival,ratioofimmunereactionsandsideeffects)wereavailableandwereexpressedasrelativerisk(RR)and95%confidenceintervals(CI).RESULTS:Sevenstudieswereincludedinthisreview.Inthecomparingofmycophenolatemofetil(MMF)withplacebo,theresultsshowedMMFcouldsignificantlyreduceimmunereactionscomparedwithplacebo(RR1.0895%Cl0.95to1.21),butnoeffectoncleargraftsurvival(RR1.1195%Cl0.90to1.35).Incleargraftsurvivalandimmunereactions,MMFandcyclosporineA(CsA)showedsimilareffect(RR1.1195%Cl0.90to1.35,andRR1.48,95%Cl0.56to3.93,respectively).Tacrolimus(FK506)andsteroidshowedsimilareffectsoncleargraftsurvivalandimmunereactions(RR0.32,95%CI0.02to6.21,andRR1.00,95%CI0.88to1.14,respectively).Nodrugrelativesideeffecthasbeenfound.CONCLUSION:MMFmayreduceimmunereactionsinbothnormal-riskandhigh-riskrejectionofpenetratingkeratoplasty.CsAandFK506showedsimilareffectsasMMF.However,duetothelackoflargeclinicaltrials,theevidenceremainweak,thequalityofevidenceswereratedasverylowtomoderate.Large,properlyrandomised,placebo-controlled,doublemaskedtrialsareneededtoevaluatetheeffectofimmunosuppressants.
简介:目的:研究角膜胶原交联方法联合那他霉素应用时的体内外抗真菌效果,为临床真菌性角膜炎的治疗提供治疗方法及实验基础。方法:采用黄曲霉菌、茄病镰刀菌、白色念珠菌三种常见致病真菌,实验组分为交联联合那他霉素组、那他霉素联合核黄素组、那他霉素联合紫外照射组、交联组,并用那他霉素组作为对照。将药物涂到有1.5麦氏浊度的真菌孢子悬液的沙堡弱琼脂培养皿的中心,10min后使用胶原交联仪照射10min,之后28℃培养36h,测量抑菌圈并进行统计学分析。制备兔眼茄病镰刀菌感染模型,按随机数字表法将模型兔随机分为模型对照组、交联治疗组、那他霉素治疗组、交联联合那他霉素治疗组,每组5只;另取5只正常兔按照角膜胶原交联疗法进行照射,5只正常对照。通过前节照相、角膜刮片、共焦显微镜等观察各组治疗结果,并在治疗结束后采用电镜观察角膜超微结构改变情况。结果:体外单独应用角膜胶原交联术,对三种真菌均无效;当交联与那他霉素联合应用时,抗真菌效果均优于对照组,且差异具有统计学意义(P<0.05);那他霉素与核黄素、那他霉素与紫外线分别联合应用时,抗菌效果与对照组比较,差异均无统计学意义(P>0.05)。针对兔真菌感染模型,那他霉素治疗组及交联联合那他霉素治疗组病程约14d,交联治疗组病程约21d;经治疗后,各治疗组均已愈合,各组角膜上皮均无缺损,新生血管较多,角膜内无菌丝;前节照相结果显示,交联联合那他霉素治疗组治疗结果优于其它各治疗组,瘢痕组织较少,角膜愈合较好,病程相对短。结论:角膜胶原交联方法联合那他霉素,可促进角膜愈合,缩短病程,增强抗真菌效果,有望为眼科临床真菌性角膜炎的治疗提供一种新的治疗技术。
简介:<正>DearSir,IamDr.HuijaeLee,fromtheSeoulIreEyeClinic,Seoul,Korea.Iwritetopresentacasereportofesotropiaafterocclusiontherapy.Amblyopiacanbecausedby
简介:目的研究分析67例小切口白内障囊外摘除人工晶状体植入术疗效。方法从2011年4月到2014年11月,选取我院的134例眼白内障合并高度近视患者进行回顾性分析,将其分为两组,其中观察组67例患者进行小切口白内障囊外摘除联合人工晶体植入术,对照组67例患者给予传统白内障囊外摘除加入人工晶体植入术治疗,分析对比两组患者的治疗疗效以及并发症情况。结果观察组脱盲率(视力≥0.05)和脱残率(视力≥0.3)占比97.01%(65/67)、92.54%(62/67),均高于对照组的94.03%(63/67)、89.55%(60/67),差异均无统计学意义(均P〉0.05);两组患者术后视力比较,差异无统计学意义(P〉0.05);观察组高眼压、悬韧带断裂、玻璃体脱出、角膜内皮水肿等并发症发生率均较对照组显著降低(P〈0.05)。结论小切口白内障囊外摘除人工晶状体植入治疗白内障高度近视术后恢复快,手术并发症少,值得临床进一步推广。
简介:AIM:Tocomparetheeffectoftopicallyadministeredandsubconjunctivallyinjectedbevacizumabonexperimentalcornealneovascularizationinratsfortwoweeksaftertreatment.METHODS:Twenty-eightSprague-Dawleyratsweredividedintofourgroupsof7animals.Eachcornealcenterofrighteyewascauterizedwithsilver/potassiumnitratefor8s.Aftercornealburning,bevacizumab(12.5mg/mL)wastopicallyadministeredthreetimesperday(TBgroup)fortwoweeksorsubconjunctivallyinjectedondays2and4aftercauterization(0.02mL;SBgroup).Asnegativecontrols,ratsreceived0.9%salinetopicallythreetimesperday(TSgroup)orsubconjunctivallyondays2and4(0.02mL;SSgroup).Digitalphotographsofthecorneaweretaken1and2weeksaftertreatmentandanalyzedtodeterminetheareaofcorneacoveredbyneovascularizationasthepercentageofcornealneovascularization.RESULTS:Oneweekaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBandSBgroupsthanintheTSandSSgroups(allP<0.05).Twoweeksaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBgroupthanintheTSgroup(P<0.05).Inallgroups,thepercentageofneovascularizationwasdecreasingastimepassed(allP<0.05)CONCLUSION:Topicallyadministeredbevacizumabhaslongerstandinganti-angiogeniceffectthansubconjunctivallyinjectedbevacizumabincornealneovascularizationfollowingchemicalinjuryinrats.
简介:目的:观察小牛血去蛋白提取物眼用凝胶对复发性翼状胬肉术后角膜切口修复的应用疗效。方法:将68例68眼行复发性翼状胬肉术后发生角膜切口水肿的患者随机分为2组,每组34例。对照组常规应用双氯芬酸钠滴眼液加抗生素滴眼液同时加用贝复舒滴眼液交替点眼,4次/d。治疗组除每日应用双氯芬酸钠滴眼液加抗生素滴眼液交替点眼外,使用小牛血去蛋白提取物眼用凝胶,4次/d,疗程1mo,于用药前和用药后3,7,14d;1mo分别对患者主觉症状、体征、角膜切口修复情况进行对比分析。结果:复发性翼状胬肉术后3,7,14d,治疗组角膜切口水肿较对照组明显消退,切口修复较快,主觉症状在短时间消退,术后1mo,两组无显著性差异。结论:小牛血去蛋白提取物眼用凝胶对复发性翼状胬肉术后角膜切口的早期修复起效时间短、舒适度好、安全性良好,对减少术后感染性角膜病的发生及术后角膜散光有良好的作用。
简介:目的通过对儿童先天性白内障人工晶体植入术的临床观察,探讨儿童人工晶体植入的最佳时机,屈光度选择以及并发症的防治.方法75例(96)眼全部施行后房型人工晶体植入术,其中无晶体眼为3眼;年龄最小2岁,最大14岁,平均7.6岁;随访4月-3年.结果1.术后矫正视力满意,≥0.5共38眼,占39%,0.1-0.4共36眼,占38%,<0.1共8眼,占8%,视力检查不合作14眼,占15%.2.术后葡萄膜炎及晶体后囊膜增殖较成人严重.结论先天性白内障人工晶体植入术是防治儿童弱视,恢复双眼单视功能的最佳方法.儿童先天性白内障应尽早手术,术后及时处理并发症并进行弱视训练.
简介:AIM:Toestablishanuntransfectedhumancornealstromal(HCS)celllineandcharacterizeitsbiocompatibilitytoacellularporcinecornealstroma(aPCS).·METHODS:PrimaryculturewasinitiatedwithapurepopulationofHCScellsinDMEM/F12media(pH7.2)containing20%fetalbovineserumandvariousnecessarygrowthfactors.Theestablishedcelllinewascharacterizedbygrowthproperty,chromosomeanalysis,tumorigenicityassay,expressionofmarkerproteinsandfunctionalproteins.Furthermore,thebiocompatibilityofHCScellswithaPCSwasexaminedthroughhistologicalandimmunocytochemistryanalysesandwithlight,electronmicroscopies.·RESULTS:HCScellsproliferatedtoconfluence2weekslaterinprimarycultureandhavebeensubculturedtopassage140sofar.AcontinuousuntransfectedHCScelllinewithapopulationdoublingtimeof41.44hoursatpassage80hasbeendetermined.Resultsofchromosomeanalysis,morphology,combinedwiththeresultsofexpressionofmarkerproteinandfunctionalproteinssuggestedthatthecellsretainedHCScellproperties.Furthermore,HCScellshavenotumorigenicity,andwithexcellentbiocompatibilitytoaPCS.·CONCLUSION:Anuntransfectedandnon-tumorigenicHCScelllinehasbeenestablished,andthecellsmaintainedpositiveexpressionofmarkerproteinsandfunctionalproteins.Thecellline,withexcellentbiocompatibilitytoaPCS,mightbeusedforinvitroreconstructionoftissue-engineeredHCS.
简介:AIM:Tocharacterizetheclinicalfeatures,diagnosis,treatmentandprognosisofuveitisassociatedwithankylosingspondylitis(AS)inChinesepatients.·METHODS:TwohundredandthreepatientswithuveitisassociatedwithASfollowed-upintheThirdMilitaryMedicalUniversityDapingHospitalbetween2005and2010wereretrospectivelyevaluatedinthisstudy.Completeophthalmologicalexaminationswereevaluatedatbaselineandduringthefollow-upperiod.Thegender,age,follow-uptime,meanfrequencyofuveitisonset,andaccompanyingeyeexaminationfindings,history,demographicalparameterswerereviewed.Allthepatientspresentedcompleteclinicalandradiologic(sacroiliac,lumbar,dorsalandcervicalspine,knee,ankle,shoulder,hip,elbow)evaluation.HLA-B27typingwasalsosearched.·RESULTS:Therewere203patientsdiagnosedwithASassociateduveitis.AllshowedsacroiliacX-raychangesindicativeofAS.Therewere184maleand19femalepatients.Theaverageageofpatientswas35±12(range18-50).Meanfollow-upperiodwas2.4years(1-5years).Acuteanterioruveitiswasthemostcommontypeofuveitisinbothgenders.121eyespresentedunilateralinvolvement(55.2%),and92eyespresentedbilateralinvolvement(45.3%)withonsetalternately.22eyesoccurredhypopyon,16eyeswerefoundanteriorvitreouscells,7eyeswerenotedreactivemacularedemaorexudation,29eyespresentedposteriorsynechiaeofiris,and14eyespresentedcataract,9eyespresentedsecondaryglaucoma,2eyespresentedbendcornealdegenerationand1eyespresentedatrophyofeyeball.Atthefinalvisit,uveitiswaswellcontrolledinmostpatients.·CONCLUSION:ASassociatedwithuveitisinChinesepatientsmainlymanifestsasacuteanterioruveitis.AcombinationofcorticosteroidswithothermydriasisagentsiseffectiveformostASassociatedwithuveitispatients.Ingeneral,theprognosisisgoodinthesecases.
简介:AIM:Tocharacterizetemporalpatternofresolutionandrecurrenceofnaivechoroidalneovascularization(CNV)secondarytowetage-relatedmaculardegeneration(AMD)treatedwithintravitrealbevacizumabonasneededregimen,andtoanalyzebaselineriskfactorsforCNVresolutionorrecurrence.METHODS:Ninety-oneeyesof80patientswithnewlydiagnosedwetAMDwereretrospectivelystudied.Alleyesweretreatedwitharoundofthreemonthlyintravitrealbevacizumabinjections,followedbyoneadditional’bonus’injectionafterresolutionofCNVactivity.Duringfollow-up,eyesweremonitoredwithfluoresceinangiography,opticalcoherencetomography,andbest-correctedvisualacuity(BCVA).IncaseofrecurrencesofCNVactivity,eyeswereretreatedwithotherroundsofbevacizumabinjectionsfollowingthesametreatmentprotocol.RESULTS:Overamedianfollow-upof532d,themedianresolutiontimeofCNVactivityinthefirst,second,andthirdtreatmentroundwas98d,126d,and111d,respectively.Themedianrecurrencetimeforthethreeroundswas154d,126d,and151d,respectively.Nosignificantdifferenceinresolutiontime(P=0.09)orinrecurrencetime(P=0.11)wasdetectedamongtreatmentrounds.Age(P=0.0082)andlensstatus(P=0.035)werefoundtobeassociatedwithCNVresolution;forevery1-yearincreaseinagetherewas4%greaterchanceofCNVresolution;Phakiceyesdemonstrateda33%betterchancetoexperienceCNVresolutionthanpseudophakiceyes.ForCNVrecurrence,lensstatus(P=0.0009)andgender(P=0.0446)werefoundtobepredictive;pseudophakiceyeshada3.69-foldgreaterrisktoexperiencerecurrenceofCNVactivitycomparedtophakiceyes;maleshada2.19-foldgreaterrisktoexperiencerecurrenceofCNVactivitythanfemales.NosignificantBCVAchangesamongthreetreatmentroundswerenoted(P=0.56).CONCLUSION:ResolutiontimeandrecurrencetimeofCNVactivitywerenotsignificantlydifferentamongtreatmentrounds,suggestingabsenceoftachyphylaxistobevacizumab.Acautiousdecisionshouldbemadeupondisco